Brief: Enliven Therapeutics And Imara Announce Merger Agreement

Enliven Therapeutics

13/10/2022 21:41

Oct 13 (Reuters) - Imara Inc  IMRA.O :
    * ENLIVEN THERAPEUTICS AND IMARA ANNOUNCE MERGER AGREEMENT
    * IMARA INC - COMBINED COMPANY IS EXPECTED TO HAVE A CASH
BALANCE
OF APPROXIMATELY $300 MILLION AT CLOSE
    * IMARA INC - UPON CLOSING OF PROPOSED TRANSACTION, IMARA
INC.
WILL BE RENAMED ENLIVEN THERAPEUTICS, INC.
    * IMARA INC - IN SUPPORT OF MERGER, ENLIVEN ALSO INTENDS TO
RAISE
APPROXIMATELY $165 MILLION IN A CONCURRENT PRIVATE FINANCING
    * IMARA INC - COMBINED COMPANY WILL BE LED BY SAM KINTZ,
CO-FOUNDER AND CHIEF EXECUTIVE OFFICER OF ENLIVEN, AND OTHER
MEMBERS OF ENLIVEN MANAGEMENT TEAM
    * IMARA INC -  CASH BALANCE OF APPROXIMATELY $300 MILLION IS
EXPECTED TO PROVIDE CASH RUNWAY THROUGH MULTIPLE CLINICAL
MILESTONES AND INTO EARLY 2026
    * IMARA INC - UPON COMPLETION OF MERGER, COMBINED CO IS
EXPECTED
TO OPERATE UNDER NAME ENLIVEN THERAPEUTICS, INC.
    * IMARA INC - UPON COMPLETION OF MERGER, COMBINED CO IS
EXPECTED
TRADE ON NASDAQ GLOBAL SELECT MARKET UNDER TICKER SYMBOL ELVN

Source text for Eikon:  ID:nGNXbv822D 
Further company coverage:  IMRA.O 
 ((Reuters.Briefs@thomsonreuters.com;))